Mesa Laboratories, Inc. (MLAB) Stock

Mesa Laboratories, Inc. (MLAB) is a Technology stock trading at $119.25 (as of 2026-08-20), with a market capitalization of $667.28M and a trailing P/E of 48.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences instruments and quality control products and services. Its Sterilization and Disinfection Control offerings include indicators for validating sterilization and disinfection and related testing and laboratory services, while its Biopharmaceutical Development segment provides automated protein analysis systems and peptide synthesis solutions.

Understand Mesa Laboratories, Inc.: how it makes money

Mesa Laboratories develops, manufactures, and sells life sciences tools and quality control products and services, including sterilization and disinfection indicators and related testing services, to customers such as hospitals, dental providers, medical device companies, and pharmaceutical organizations, and it earns money from division product and service sales.

The company monetizes ongoing, regulated testing needs by selling sterilization and disinfection indicators and providing related testing and laboratory services, so the revenue mix across these life sciences and quality control divisions drives overall results.

Revenue by segment (latest quarter)
Sterilization$0.0B
ClinicalGen$0.0B
BiopharmaDev$0.0B
CalibSol$0.0B
GKE$0.0B
Other$0.0B

Business quality (Mixed): Good directional fit to the business description using division revenue labels as segment proxies, but the provided division revenues do not sum to the stated total revenue, so the remaining gap is shown as an unallocated Other bucket.

Valuation: At 79× earnings, MLAB trades 31% above the Measuring & Control Equipment average (60×). Note: one-time items can distort reported P/E.

Bull case

  • Mission critical, process verification focus: Sterilization and disinfection control indicators are used to assess the effectiveness of sterilization and disinfection processes in hospitals, dental, medical device, and pharmaceutical industries.
  • Services component alongside products: The sterilization and disinfection control segment also provides testing and laboratory services primarily to the dental industry, which can support a broader customer relationship than products alone.
  • Diversification across multiple life sciences offerings: In addition to sterilization and disinfection control, the company has separate divisions labeled Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions.

Bear case

  • Customer spending sensitivity: Because products are used in sterilization and disinfection and clinical settings, any slowdown in hospital, dental, or pharmaceutical related testing and process assessment demand could pressure division revenues.
  • Mix risk across smaller divisions: Several divisions are each shown at relatively small revenue levels, so changes in mix across Sterilization, Clinical Genomics, Biopharmaceutical Development, Calibration Solutions, and GKE contributed revenues could materially affect consolidated performance.
  • Contribution label indicates non core complexity: The presence of a dedicated line item for GKE contributed revenues suggests a specific revenue stream that may have different drivers than the rest of the portfolio.
Valuation — source: SEC EDGAR (first-party)
Price$119.25
Market Cap$667.28M
P/E Ratio48.8
EV / EBITDA25.1
Price / Book3.54
Price / Sales2.72
FCF Yield7.4%
DCF Value (model)$6.22
DCF Upside vs Price-94.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$249.13M
Net Margin2.7%
Revenue Growth (YoY)3.4%
EPS Growth (YoY)-438.9%
FCF Growth (YoY)-7.0%
Financial Health — source: SEC EDGAR
Altman Z-Score1.88 (grey)
Piotroski F-Score8/9 (strong)
Valuation vs Sector & Industry
Stock P/E48.8
Sector P/E (Technology)33.9
Industry P/E (Measuring & Control Equipment)51.8
vs Sector43.8%
vs Industry-5.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderLong Path Partners LP ($35.86M)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEOGary Owens
Employees736
CountryUS
IPO Date1984-02-29

Related Companies (Business model: Industrials / Capital Goods (Heavy Machinery + Diversified Industrials); 8 closest by market cap; US-domiciled)

  • Ralliant Corp. (RAL)
  • Sensata Technologies Holding plc (ST)
  • Transcat, Inc. (TRNS)
  • Frequency Electronics, Inc. (FEIM)
  • Senseonics Holdings, Inc. (SENS)
  • Syntec Optics Holdings, Inc. (OPTX)
  • Hurco Companies, Inc. (HURC)
  • Sypris Solutions, Inc. (SYPR)
MLAB earnings history · MLAB institutional & insider holders · MLAB KPIs & operating metrics · MLAB financials · MLAB investor presentations & press releases · MLAB SEC filings · MLAB peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.